By Chris Wack Immutep Limited is in a new collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, for a Phase I/IIa clinical trial in patients with solid tumors. The. | June 1, 2021
Investegate announcements from Basilea Pharmaceutica AG, Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clinical programs in urothelial and gastric cancer
Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
News provided by
Share this article
Share this article
AUSTIN, Texas, May 28, 2021 /PRNewswire/ Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal s™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests.
Natera has filed a claim against Guardant in the U.S. District Court for the Western District of Texas, (Docket No.6:21-cv-00540), alleging that Guardant used false and misleading claims to deceive physicians about the performance capabilities of its MRD test, in violation of the Lanham Act. Guardant s MRD test performance claims are incomplete or unsupported by clinical evidence, and can be misinterpreted by physicians and patients.
/PRNewswire/ Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision.
Rain Therapeutics Appoints Robert Doebele, M D , Ph D as President Dr Doebele, Rain co-founder, will continue to serve as chief scientific officer biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.